Şunu aradınız:: hiperkoagulacije (Slovence - İngilizce)

lpld vključuje stanje hiperviskoznosti/hiperkoagulacije.
lpld involves a state of hyperviscosity/hypercoagulability.

poleg tega ni dokaza za zmožnost hiperkoagulacije, saj so imele zdrave osebe, ki so prejemale telavancin običajne ravni d-dimera in produktov razgradnje fibrina.
furthermore, no evidence of hypercoagulability has been seen, as healthy subjects receiving telavancin have normal levels of d-dimer and fibrin degradation products.

intravenske imunoglobulinske pripravke morate predpisovati in infundirati previdno pri bolnikih s čezmerno telesno maso, bolnikih s prisotnimi dejavniki tveganja za trombotične dogodke (kot so ateroskleroza v anamnezi, več kardiovaskularnih dejavnikov tveganja, višja starost, slabši minutni volumen srca, hipertenzija, uporaba estrogenov, sladkorna bolezen in bolezni ožilja ali trombotične epizode v anamnezi, bolnikih s pridobljenimi ali dednimi trombofilnimi boleznimi, boleznimi hiperkoagulacije, dolgotrajno imobiliziranih bolnikih, močno hipovolemičnih bolnikih, bolnikih z boleznimi, ki povečajo viskoznost krvi, bolnikih s stalnim vaskularnim katetrom ter bolnikih z visokimi odmerki in hitrim infundiranjem).
caution should be exercised in prescribing and infusion of ivig in obese patients and in patients with pre-existing risk factors for thrombotic events (such as a history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, hypertension, use of estrogens, diabetes mellitus and a history of vascular disease or thrombotic episodes, patients with acquired or inherited thrombophilic disorders, hypercoagulable disorders, patients with prolonged periods of immobilisation, severely hypovolemic patients, patients with diseases which increase blood viscosity, patients with indwelling vascular catheters and patients with high dose and rapid infusion).